<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Allergy</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Allergy</journal-id><journal-title-group><journal-title>Clinical and Translational Allergy</journal-title></journal-title-group><issn pub-type="epub">2045-7022</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3716515</article-id><article-id pub-id-type="publisher-id">2045-7022-3-S2-P43</article-id><article-id pub-id-type="doi">10.1186/2045-7022-3-S2-P43</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Acoustic rhinometry after nasal provocation test, 6 months interim analysis of alumites study, a randomized, controlled, multicentre phase IV study with house dust mites subcutaneous immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Sanchez</surname><given-names>Jaime</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Vidal</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Hernandez</surname><given-names>Dolores</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Valero</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Castello</surname><given-names>Jose Vicente</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Pelaez</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Garcia</surname><given-names>Mario Alberto</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib></contrib-group><aff id="I1"><label>1</label>Hospital Clinic Universitari de Barcelona, Allergy Service, Barcelona, Spain</aff><aff id="I2"><label>2</label>Complejo Hospitalario de Santiago. Hospital del Conxo, Allergy Service, Santiago de Compostela, Spain</aff><aff id="I3"><label>3</label>Hospital Universitario y Politecnico La Fe, Allergy Service, Valencia, Spain</aff><aff id="I4"><label>4</label>Hospital General de Castellon, Allergy Service, Castellon, Spain</aff><aff id="I5"><label>5</label>Hospital Clinico Universitario de Valencia, Allergy Service, Valencia, Spain</aff><aff id="I6"><label>6</label>Stallergenes Iberica, Medical Department, Barcelona, Spain</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>16</day><month>7</month><year>2013</year></pub-date><volume>3</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">9th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2013): Abstracts</named-content><named-content content-type="supplement-editor">Peter W Hellings, Claus Bachert, Philippe Gevaert, Philippe Rombaux, Cemal Cingi, Carmen Rondon, Felicia Manole, Zeljka Roje, Elina Toskala, Gianni Passalacqua, Valerie Hox, Michael Rudenko, Cezmi Akdis and Christian Virchow</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by the European Academy of Allergy and Clinical Immunology (EAACI).</named-content></supplement><fpage>P43</fpage><lpage>P43</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Sanchez et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Sanchez et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.ctajournal.com/content/3/S2/P43"/><conference><conf-date>21-23 March 2013</conf-date><conf-name>9th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2013)</conf-name><conf-loc>Leuven, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>ALUMITES study was designed to assess the efficacy of house dust mites (HDM: <italic>D. pteronyssinus</italic> + <italic>D. farinae</italic>) subcutaneous immunotherapy for the treatment of allergic rhinitis patients along one year. Here we report an interim analysis done after 6 months of treatment.</p></sec><sec sec-type="methods"><title>Methods</title><p>In this controlled multicentre phase IV study, HDM adult allergic patients were randomized to receive subcutaneous immunotherapy with a 10 IR/ml depot extract plus symptomatic treatment (group A) or only symptomatic treatment (group B) (2:1). Acoustic rhinometry after nasal provocation test (NPT) was selected to objectively assess the efficacy of this treatment by measuring the nasal volume (NV) and minimum cross-sectional area (MCA). A visual analogic scale (VAS) has been used to subjectively assess the efficacy (0-10 scale, lower is better)NPT consists in 5 determinations at intervals of 15 minutes (basal, diluent, 0.01 IR, 0.1 IR, 1 IR) and one last determination 30 minutes after the last administration. The extract used for the NPT was 100 IR/ml of <italic>D. pteronyssinus</italic>.</p></sec><sec sec-type="results"><title>Results</title><p>Data from 38 of 57 patients were complete to be analyzed. MCA difference from baseline to six months visit was 1.6 cm<sup>2</sup> (95% CI: [-2.1, 5.3]) in active group and 0.8 cm<sup>2</sup> (95% CI: [-4.3, 5.9]) in control group. NV difference from baseline to six months visit was 37.1 cm<sub>3</sub> (95% CI: [-16.9, 91.2]) in active group and -5.8 cm3 (95% CI: [-75.6, 64]) in control group. The analysis of covariance (ANCOVA) showed statistical differences in basal determination of MCA after 6 months treatment (p=0.0001).The symptoms score after the last provocation of 1 IR measured by VAS from baseline to the six month visit had a reduction of -2.4 points (95% CI: [-3.2, -1.6], p&#x0003c;0.0001) in the active group whereas there was no statistical reduction in the control group: -0.7 points (95% CI: [-2.5, 1.0], p=0.577).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Despite of the final low sample to analyze, efficacy is demonstrated with six months of SCIT treatment with 10 IR/ml depot HDM extract that resulted in a significant improve in clinical symptoms, this improvement was not achieved by the control group. Objective assessment of efficacy shows a clear positive trend in minimal cross-sectional area determination.</p></sec></body></article>